EFFECTS OF HUMANIZED MONOCLONAL ANTIBODY TO RHESUS CD11a IN RHESUS MONKEY CARDIAC ALLOGRAFT RECIPIENTS12

Abstract

The use of this mAb to block CD11a had the benefit of being a well tolerated, highly targeted therapy. These are the first results showing that monotherapy with anti-leukocyte function-associated antigen-1 mAb prolonged survival of MLR mismatched allogenic cardiac grafts in primates.